Review
References
|
Afriyie DK, Amponsah SK, Antwi R, Nyoagbe SY, Bugyei KA (2015). Prescribing trend of antimalarial drugs at the Ghana Police Hospital. J. Infect. Dev. Ctries 9(04):409-415. |
|
|
Agbo HA, Madaki A, Envuladu E (2012). Exploring the Prevalence of Malaria and Prescribing Pattern of Antimalarial Treatment at an Urban Primary Health Care Centre. Jos J. Med. 6(2):59-62. |
|
|
Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC (2009). Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am. J. Trop. Med. Hyg. 80(4):523-527. |
|
|
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L (2014). A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505(7481):50-55. |
|
|
Banek K, Lalani M, Staedke SG, Chandramohan D (2014). Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar. J. 13(1):7. |
|
|
Bello SO, Chika A, AbdulGafar JO (2010). Artesunate plus Amodiaquine (AS+ AQ) versus Artemether-Lumefantrine (AL) for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa-a meta-analysis. Afr. J. Infect. Dis. 4(2):20-28. |
|
|
Bonnet M, Broek Ivd, van Herp M, Urrutia P, van Overmeir C, Kyomuhendo J, Ndosimao CN, Ashley E, Guthmann J-P (2009). Varying efficacy of artesunate+ amodiaquine and artesunate+ sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar. J. 8(1):192. |
|
|
Builders MI, Degge H, Peter JY, Ogbole E (2014). Prescription pattern of antimalarial drugs in a Teaching Hospital in Nigeria. Br. Biomed. Bull. 2(1):267-276. |
|
|
Burda BU, Norris SL, Holmer HK, Ogden LA, Smith ME (2011). Quality varies across clinical practice guidelines for mammography screening in women aged 40-49 years as assessed by AGREE and AMSTAR instruments. J. Clin. Epidemiol. 64(9):968-76. |
|
|
Chandler CI, Mwangi R, Mbakilwa H, Olomi R, Whitty CJ, Reyburn H (2008). Malaria overdiagnosis: is patient pressure the problem? Health policy Plan. 23(3):170-178. |
|
|
Diala CC, Pennas T, Marin C, Belay KA (2013). Perceptions of intermittent preventive treatment of malaria in pregnancy (IPTp) and barriers to adherence in Nasarawa and Cross River States in Nigeria. Malar. J. 12(1):1-16. |
|
|
Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su X-z, Nomura T (2001). A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344(4):257-263. |
|
|
Dose WARNWA, Group IS (2015). The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect. Dis. 15(6):692-702. |
|
|
Eisele T, Larsen D, Walker N, Cibulskis R, Yukich J, Zikusooka C (2012). Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001–2010. Malar. J. 11:93. |
|
|
El-Jardali F, Akl EA, Fadlallah R, Oliver S, Saleh N, El-Bawab L, Rizk R, Farha A, Hamra R (2015). Interventions to combat or prevent drug counterfeiting: a systematic review. BMJ open 5(3):e006290. |
|
|
Elmannan AA, Elmardi KA, Idris YA, Spector JM, Ali NA, Malik EM (2015). Anti-malarial prescribing practices in Sudan eight years after introduction of artemisinin-based combination therapies and implications for development of drug resistance. BMC Pharmacol. Toxicol. 16(1):3. |
|
|
Ezenduka CC, Okonta MJ, Esimone CO (2014). Adherence to treatment guidelines for uncomplicated malaria at two public health facilities in Nigeria; Implications for the 'test and treat'policy of malaria case management. J. Pharm. Policy Pract. 7(1):15. |
|
|
Faye B, Offianan AT, Ndiaye JL, Tine RC, Touré W, Djoman K, Sylla K, Ndiaye PS, Penali L, Gaye O (2010). Efficacy and tolerability of artesunateâ€amodiaquine (Camoquin plus®) versus artemetherâ€lumefantrine (Coartem®) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop. Med. Int. Health 15(5):608-613. |
|
|
Frank M, Lehners N, Mayengue PI, Gabor J, Dal-Bianco M, Kombila DU, Ngoma GM, Supan C, Lell B, Ntoumi F (2011). A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon. Malar. J. 10(1):304. |
|
|
Frenk J (2010). The global health system: strengthening national health systems as the next step for global progress. PLos Med. 7(1):e1000089. |
|
|
Fuangchan A, Dhippayom T, Kongkaew C (2014). Intervention to promote patients' adherence to antimalarial medication: a systematic review. Am. J. Trop. Med. Hyg. 90(1):11-19. |
|
|
Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M (2015). Effective Coverage and Systems Effectiveness for Malaria Case Management in Sub-Saharan African Countries. PloS one 10(5):e0127818. |
|
|
Gelband H, Laxminarayan R (2015). Tackling antimicrobial resistance at global and local scales. Trends Microbiol. 23(9):524-526. |
|
|
Gelband H, Panosian C, Arrow KJ (2004). Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. edn. National Academies Press. |
|
|
Gosling R, Okell L, Mosha J, Chandramohan D (2011). The role of antimalarial treatment in the elimination of malaria. Clin. Microbiol. Infect. 17(11):1617-1623. |
|
|
Group AS (2015). The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 13(1):66. |
|
|
Group DS (2013). The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. PLoS Med. 10(12):1-17. |
|
|
Group FA-BCS (2011). A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 8(11):e1001119. |
|
|
Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda P, Sipilinyambe N, Simon JL, Snow RW (2007). Improved diagnostic testing and malaria treatment practices in Zambia. JAMA 297(20):2227-2231. |
|
|
Happi C, Gbotosho G, Folarin O, Bolaji O, Sowunmi A, Kyle D, Milhous W, Wirth D, Oduola A (2006). Association between mutations in plasmodium falciparum chloroquine resistance transporter and p. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in p. falciparum malaria–infected children in Nigeria. Am. J. Trop. Med. Hyg. 75(1):155-161. |
|
|
Harrison N, Olufunlayo T, Agomo C (2012). Utilization of the current national antimalarial treatment guidelines among doctors in army hospitals in Lagos, Nigeria. Open J. Prev. Med. 2(3):390-393. |
|
|
Harrison NE, Olufunlayo TF, Odunukwe NN (2013). Prescription of intermittent preventive therapy (IPTp) among doctors practicing in an army hospital in Lagos, Nigeria. Open J. Prev. Med. 3(2):258-261. |
|
|
Hill J, D'Mello-Guyett L, Hoyt J, van Eijk AM, ter Kuile FO, Webster J (2014). Women's Access and Provider Practices for the Case Management of Malaria during Pregnancy: A Systematic Review and Meta-Analysis. PLoS Med. 11(8):e1001688. |
|
|
Hill J, Hoyt J, van Eijk AM, D'Mello-Guyett L, ter Kuile FO, Steketee R, Smith H, Webster J (2013). Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 10(7):e1001488. |
|
|
Isiguzo C, Anyanti J, Ujuju C, Nwokolo E, De La Cruz A, Schatzkin E, Modrek S, Montagu D, Liu J (2014). Presumptive treatment of malaria from formal and informal drug vendors in Nigeria. PloS one 9(10):e110361. |
|
|
Karunamoorthi K (2014). The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar. J. 13(1):209-209. |
|
|
Krause G, Sauerborn R (2000). Comprehensive community effectiveness of health care. A study of malaria treatment in children and adults in rural Burkina Faso. Ann. Trop. Paediatr: Int. Child Health 20(4):273-282. |
|
|
Kyabayinze DJ, Asiimwe C, Nakanjako D, Nabakooza J, Counihan H, Tibenderana JK (2010). Research Use of RDTs to improve malaria diagnosis and fever case management at primary health care facilities in Uganda. Malar. J. 9(1):200. |
|
|
Lussiana C (2015). Towards subsidized malaria rapid diagnostic tests. Lessons learned from the global subsidy of artemisinin-based combination therapies: a review. Health Policy plan.1:12. |
|
|
Mbacham WF, Mangham-Jefferies L, Cundill B, Achonduh OA, Chandler CI, Ambebila JN, Nkwescheu A, Forsah-Achu D, Ndiforchu V, Tchekountouo O (2014). Basic or enhanced clinician training to improve adherence to malaria treatment guidelines: a cluster-randomised trial in two areas of Cameroon. Lancet Glob. Health 2(6):e346-e358. |
|
|
Mbonye AK, Birungi J, Yanow S, Magnussen P (2013). Prescription patterns and drug use among pregnant women with febrile Illnesses in Uganda: A survey in out-patient clinics. BMC Infect. Dis. 13(1):237. |
|
|
Mbonye MK, Burnett SM, Burua A, Colebunders R, Crozier I, Kinoti SN, Ronald A, Naikoba S, Rubashembusya T, Willis KS (2014). Effect of integrated capacity-building interventions on malaria case management by health professionals in Uganda: A mixed design study with pre/post and cluster randomized trial components. PloS one 9(1):e84945. |
|
|
Menard S, Morlais I, Tahar R, Sayang C, Mayengue PI, Iriart X, Benoit-Vical F, Lemen B, Magnaval JF, Awono-Ambene P (2012). Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaounde, Cameroon: implications for the future. Malar. J. 11:113. |
|
|
Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, Chotivanich K, Imwong M, Pukrittayakamee S, Dhorda M (2015). Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347(6220):431-435. |
|
|
Mussa S, Gedif T (2013). Antimalarial Drug Use Pattern in Pawe Special Woreda, North West Ethiopia: A Community Based Survey. Ethiop. Pharm. J. 29(2):121-136. |
|
|
Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M (2009). Chloroquine resistance before and after its withdrawal in Kenya. Malar. J. 8(1):106. |
|
|
Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA (2009). Randomized, multicentre assessment of the efficacy and safety of ASAQ–a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J. 8(1):125. |
|
|
Ndyomugyenyi R, Magnussen P, Clarke S (2007). Malaria treatment-seeking behaviour and drug prescription practices in an area of low transmission in Uganda: implications for prevention and control. Trans. R. Soc. Trop. Med. Hyg. 101(3):209-215. |
|
|
Newton PN, Green MD, Mildenhall DC, Plançon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K (2011). Poor quality vital anti-malarials in Africa-an urgent neglected public health priority. Malar. J. 10:352. |
|
|
Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I, Rueda ST, Kiefer S, O'Connell KA, Zinsou C (2014). Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries. PloS one 9(4):e93763. |
|
|
Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I, Rueda ST, Kiefer S, O'Connell K, Zinsou C (2015). Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries. Health Policy Plan. 1: 1-13. |
|
|
Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA (2015). The public health impact of malaria vaccine RTS, S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med. 13(1):170. |
|
|
Pink R, Hudson A, Mouriès M-A, Bendig M (2005). Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 4(9):727-740. |
|
|
Rabiu KA, Davies NO, Nzeribe-Abangwu UO, Adewunmi AA, Akinlusi FM, Akinola OI, Ogundele SO (2015). Malaria prevention and treatment in pregnancy: Survey of current practice among private medical practitioners in Lagos, Nigeria. Trop. Doct. 45(1):6-11. |
|
|
Rao VB, Schellenberg D, Ghani AC (2013). Overcoming health systems barriers to successful malaria treatment. Trends Parasitol. 29(4):164-180. |
|
|
Renschler JP, Walters K, Newton PN, Laxminarayan R (2015). Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa. Am. J. Trop. Med. Hyg. 92(6 Suppl):119-126. |
|
|
Research mCGoHSaO (2011). A Research Agenda for Malaria Eradication: Health systems and operational research. PLoS Med. 8:e1000397. |
|
|
Romay-Barja M, Jarrin I, Ncogo P, Nseng G, Sagrado MJ, Santana-Morales MA, Aparcio P, Valladares B, Riloha M, Benito A (2015). Rural-Urban Differences in Household Treatment-Seeking Behaviour for Suspected Malaria in Children at Bata District, Equatorial Guinea. PloS one 10(8):e0135887. |
|
|
Rowe AK, De Leon G, Mihigo J (2009). Quality of malaria case management at outpatient health facilities in Angola. Malar. J. 8(1):275. |
|
|
Salissou A, Zamanka H, Biyghe Binze B, Rivière T, Tichit M, Ibrahim ML, Fandeur T (2014). Low prevalence of Pfcrt resistance alleles among patients with uncomplicated Falciparum malaria in Niger six years after chloroquine withdrawal. Malar. Res. Treat. 2014:614190. |
|
|
Shengelia B, Tandon A, Adams OB, Murray CJ (2005). Access, utilization, quality, and effective coverage: An integrated conceptual framework and measurement strategy. Soc. Sci. Med. 61(1):97-109. |
|
|
Sidhu ABS, Verdier-Pinard D, Fidock DA (2002). Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298(5591):210-213. |
|
|
Sirima SB, Tiono AB, Gansané A, Diarra A, Ouédraogo A, Konaté AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WR (2009). The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar. J. 8(1):48. |
|
|
Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S (2015). K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347(6220):428-431. |
|
|
Tabernero P, Fernández FM, Green M, Guerin PJ, Newton PN (2014). Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the WorldWide Antimalarial Resistance Network database. Malar. J. 13:139. |
|
|
Tambo E, Adedeji A, Huang F, Chen J, Zhou S, Tang L (2012). Scaling up impact of malaria control programmes: a tale of events in Sub-Saharan Africa and Peoples Republic of China. Infect. Dis. Poverty 1:1-15. |
|
|
Tanahashi T (1978). Health service coverage and its evaluation. Bull. World Health Organ. 56:295-303. |
|
|
Tanner M, Vlassoff C (1998). Treatment-seeking behaviour for malaria: a typology based on endemicity and gender. Soc. Sci. Med. 46:523-532. |
|
|
Van Hong N, Amambua-Ngwa A, Tuan NQ, Cuong DD, Giang NTH, Van Dung N, Tinh TT, Van Tien N, Phuc BQ, Duong TT (2014). Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg. Infect. Dis. 20(7):1207. |
|
|
Van Tyne D, Dieye B, Valim C, Daniels RF, Sène PD, Lukens AK, Ndiaye M, Bei AK, Ndiaye YD, Hamilton EJ (2013). Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal. Malar. J. 12:441. |
|
|
Verret WJ, Arinaitwe E, Wanzira H, Bigira V, Kakuru A, Kamya M, Tappero JW, Sandison T, Dorsey G (2011). Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob. Agents Chemother. 55(6):2629-2635. |
|
|
White NJ (2002). The assessment of antimalarial drug efficacy. Trends Parasitol. 18(10):458-464. |
|
|
World Health Organization (WHO) (2001). Antimalarial drug combination therapy. Geneva: World Health Organisation. |
|
|
World Health Organization (WHO) (2005). Combating counterfeit drugs: a concept paper for effective international collaboration. Geneva: World Health Organization. |
|
|
World Health Organization (WHO) (2015). Guidelines for the treatment of malaria. Geneva. Report no. 9241549122 |
|
|
World Health Organization (WHO) (2014). World malaria report 2014. Geneva: World Health Organization. |
|
|
Yakasai AM, Hamza M, Dalhat MM, Bello M, Gadanya MA, Yaqub ZM, Ibrahim DA, Hassan-Hanga F (2015). Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-Analysis. J. Trop. Med. 2015:189232. |
|
|
Yunusa A, Bello SO, Chika A (2015). Computational drug re-positioning: An approach to discover novel antimalarials. Int. J. Latest Res. Sci. Technol. 4(2):119-127. |
|
|
Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D'Alessandro U, Djimdé A, Karema C (2009). Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar. J. 8(1):203. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
